Critical Contrast: Nabriva Therapeutics (NASDAQ:NBRV) and Shiseido (OTCMKTS:SSDOY)

Nabriva Therapeutics (NASDAQ:NBRV) and Shiseido (OTCMKTS:SSDOY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Institutional & Insider Ownership

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Shiseido shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Nabriva Therapeutics and Shiseido’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59 million	0.00	-$57.19 million	($19.20)	N/A
Shiseido	$6.94 billion	1.52	$155.11 million	$0.39	67.64

Shiseido has higher revenue and earnings than Nabriva Therapeutics. Nabriva Therapeutics is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nabriva Therapeutics and Shiseido’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Shiseido	2.26%	3.42%	1.70%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Nabriva Therapeutics and Shiseido, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0	0	0	0	N/A
Shiseido	0	0	0	0	N/A

Volatility & Risk

Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Shiseido has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.

Summary

Shiseido beats Nabriva Therapeutics on 7 of the 10 factors compared between the two stocks.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

About Shiseido

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.